Impact of protein supplementation on running-induced muscle soreness and muscle damage

Impact of protein supplementation on running-induced muscle soreness and muscle damage - Prorunning

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON46050

Enrollment

416

Registered

2018-10-09

Start date

2018-11-02

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

muscle damage Muscle soreness

Interventions

Participants will be randomly allocated to one of the two groups. Participants will be instructed to ingest the protein or placebo supplement: 1) directly after finishing the running event, 2) prior

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Between 30 and 60 years of age - Registered for the 2018 Seven H ills Run (Zevenheuvelenloop) - Able to understand and perform the study procedures

Exclusion criteria

Exclusion criteria: - Muscle sorene ss and muscle complaints in daily life (unrelated to exercise) upon enrolment - Type I or type II diabetes - Allergic or sensitive for milk proteins, eggs and soybeans, or lactose intolerant. - Having been diagnosed with intestinal diseases, which will influence the uptake of protein (i.e. active inflammatory bowel disease, Crohn*s disease) - Having been diagnosed with renal insufficiency - Use of statins

Design outcomes

Primary

Measure	Time frame
The primary outcome in this study is muscle soreness at 24 hours after the exercise event for which the visual analog scale (VAS) will be used.	—

Secondary

Measure	Time frame
Secondary outcome measures include the VAS score at 48 and 72 hours after the event, the Short-Form Brief Pain Inventory (BPI-SF) questionnaire to examine muscle soreness and muscle complaints and the Short-Form Brief Fatigue Inventory (BFI-SF) to assess the level of fatigue. Moreover, in a subsample of 50% (n=208) one venous blood sample will be collected between 24 to 48 hours post-exercise to determine the muscle damage markers CK and lactate dehydrogenase (LDH) concentrations. In the same subsample perceived muscle soreness measured will be measured with a strain gauge algometer. Other important outcomes are habitual protein ingestion using a 24h recall, protein intake on the race day and 2 days post-exercise, medical history, rating of perceived exertion during the race, finish times, average heart rate during the run, training status and habitual physical activity and exercise training levels using the Short QUestionnaire to Assess Health-enhancing physical activity (SQUASH) and whether participants performed other exercises in the 2 days after the race.	—

Measure

Time frame

Secondary outcome measures include the VAS score at 48 and 72 hours after the event, the Short-Form Brief Pain Inventory (BPI-SF) questionnaire to examine muscle soreness and muscle complaints and the Short-Form Brief Fatigue Inventory (BFI-SF) to assess the level of fatigue. Moreover, in a subsample of 50% (n=208) one venous blood sample will be collected between 24 to 48 hours post-exercise to determine the muscle damage markers CK and lactate dehydrogenase (LDH) concentrations. In the same subsample perceived muscle soreness measured will be measured with a strain gauge algometer. Other important outcomes are habitual protein ingestion using a 24h recall, protein intake on the race day and 2 days post-exercise, medical history, rating of perceived exertion during the race, finish times, average heart rate during the run, training status and habitual physical activity and exercise training levels using the Short QUestionnaire to Assess Health-enhancing physical activity (SQUASH) and whether participants performed other exercises in the 2 days after the race.

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)